In the United States, there are approximately 15,000 sarcoma cases annually, comprising more than 60 types of soft tissue sarcomas and 20 types of bony sarcomas.
Patients with advanced sarcomas that have metastasized or that cannot be cured with surgery are commonly treated with doxorubicin chemotherapy. Recent findings show that adding the new targeted antibody olaratumab (Lartruvo) in combination with doxorubicin improves progression-free survival and overall survival in patients with advanced sarcomas.
‘Patients with advanced sarcomas that have metastasized or that cannot be cured with surgery are commonly treated with doxorubicin chemotherapy.’
AdvertisementOncologist Dr. Arun Singh is an assistant professor and co-director of the sarcoma program in the division of hematology/oncology in the David Geffen School of Medicine at UCLA. Dr. Singh's research is focused on developing novel therapies for patients with sarcomas.
Dr. Singh can discuss clinical trials for sarcoma patients and immunotherapeutic approaches for managing these diseases. He can also explain what the recent FDA approval of olaratumab (Lartruvo) means for sarcoma patients and how this recent decision could change the way oncologists use traditional methods such as chemotherapy, radiation therapy and surgery to treat people with the disease.
"The Food and Drug Administration's recent approval of this sarcoma combo treatment happened during an exciting time," says Singh. "I'm currently an investigator of a large ongoing phase 3 clinical trial, and if the results are positive, the findings will continue to advance the standard of care for patients with advanced soft tissue sarcomas."
UCLA's Jonsson Comprehensive Cancer Center has more than 450 researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson Comprehensive Cancer Center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In August 2016, the Jonsson cancer center ranked among the top five cancer centers nationwide by U.S. News & World Report.